Table 6

Multivariate analysis of various clinical and EGFR IHC parameters in affecting treatment outcome

VariablesOSDFSLR controlDMa
PHR (95% CI)PHR (95% CI)PHR (95% CI)PHR (95% CI)
MOD (≤ vs. > median) 0.006 1.75 (1.2–2.6) 0.003 1.76 (1.2–2.5) 0.002 1.95 (1.3–3.0) 0.501.29 (0.6–2.7)
T stage (T1–2 vs. T3–4 0.02 1.79 (1.1–2.9) 0.02 2.39 (1.2–4.9) 0.005 1.90 (1.2–3.0) 0.251.60 (0.7–3.6)
N stage (N0 vs. N+) 0.002 2.14 (1.3–3.4) 0.003 1.94 (1.3–3.0) 0.171.39 (0.9–2.2) 0.02 3.53 (1.2–10)
KPS (90–100 vs. 60–80) 0.003 1.89 (1.3–2.9) 0.04 1.51 (1.0–2.2) 0.581.14 (0.7–1.8)0.401.38 (0.7–3.0)
Primary site (larynx vs. others) 0.003 2.61 (1.4–4.9) 0.009 2.05 (1.2–3.5) 0.540.85 (0.5–1.4)0.271.54 (0.7–3.3)
SI (≤ vs. > median)0.520.78 (0.4–1.7)0.981.01 (0.5–1.9)0.930.97 (0.5–2.0)0.611.22 (0.6–2.6)
  • a DM, distant metastasis; CI, confidence interval.